Status:
UNKNOWN
Autologous Vaccination of Stage 4 Renal Cell Carcinoma Combined With Sunitinib
Lead Sponsor:
Hadassah Medical Organization
Conditions:
Renal Cell Cancer
Eligibility:
All Genders
15-70 years
Phase:
PHASE1
PHASE2
Brief Summary
While different lines of evidence support the notion that renal cell cancer is amenable for immunologic vaccination, up to now the clinical benefit associated with vaccines has been limited. One reaso...
Detailed Description
Background: Renal cell carcinoma (RCC) constitutes around 3% of all solid tumors and cure for metastatic sidease is reported for less than 5% of patients. Together with melanoma it is considered the m...
Eligibility Criteria
Inclusion
- Metastatic renal cell cancer
- Primary/metastatic tumor for which resection seems of potential clinical benefit and fresh tissue can be obtained
- Patients for whom treatment with Sunitinib is the preferred clinical therapy
- Ecog \<2
- Willingness to participate in the trial and contribute small amounts ( up to 100cc for all the trial) of blood for immunological monitoring
- No concurrent active cancers ( excluding cancers which are not life threatening such as localized treated low grade prostate cancer,skin cancer etc)
Exclusion
- Age under 70
- Life expectancy less than 3 months
- Large tumor burden at multiple organs
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2011
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT00890110
Start Date
June 1 2009
End Date
December 1 2011
Last Update
April 29 2009
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.